DOCSLIB.ORG

For Therapy of Patients with Metastasized, Breast Cancer Pretreated with Anthracycline

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
For Therapy of Patients with Metastasized, Breast Cancer Pretreated with Anthracycline ANTICANCER RESEARCH 36: 419-426 (2016) Mitomycin C and Capecitabine (MiX Trial) for Therapy of Patients with Metastasized, Breast Cancer Pretreated with Anthracycline KATRIN ALMSTEDT1, PETER A. FASCHING1, ANTON SCHARL2, CLAUDIA RAUH1, BRIGITTE RACK3, ALEXANDER HEIN1, CAROLIN C. HACK1, CHRISTIAN M. BAYER1, SEBASTIAN M. JUD1, MICHAEL G. SCHRAUDER1, MATTHIAS W. BECKMANN1 and MICHAEL P. LUX1 1Department of Obstetrics and Gynaecology, University of Erlangen, Erlangen, Germany; 2Department of Gynecology and Obstetrics, St. Marien Hospital, Amberg, Germany; 3Department of Gynecology and Obstetrics, Ludwig Maximilian University, Munich, Germany Abstract. Background/Aim: The aim of this single-arm, (MBC) is still a challenge. The majority of patients with prospective, multicenter phase II trial (MiX) was to increase breast cancer receive an anthracycline-based regimen as first treatment options for women with metastatic breast cancer chemotherapy, in an adjuvant, neoadjuvant, or metastatic pretreated with anthracycline and taxane by evaluation of the setting. The development of drug resistance and impairment efficacy and toxicity of the combination of mitomycin C and of organ functions limits the choice of further cytotoxic capecitabine. Patients and Methods: From 03/2004 to drugs in the metastatic situation. Although many patients are 06/2007, a total of 39 patients were recruited and received willing to receive further anticancer therapy to counteract mitomycin C in combination with capecitabine. The primary tumor growth, they often request a less toxic but still end-point was to determinate the tumor response according effective therapy. At present taxanes (e.g. paclitaxel, to Response Evaluation Criteria in Solid Tumors and the rate docetaxel, nab-paclitaxel), eribulin, vinorelbine, 5- of toxicities (safety). The secondary study objective was the fluorouracil (5-FU infusion, capecitabine per os) and evaluation of the time to progression (i.e. efficacy). Results: mitomycin C are widely used for salvage therapy in patients The median time to progression was 9.3 months (95% with metastatic breast cancer (2-5). confidence interval=6.6-12.0 months) and the median Mitomycin C has a well-studied therapeutic activity in survival was 12.8 months (95% confidence interval=6.8-18.8 metastatic breast cancer (6) as a result of its lack of cross- months). Most treatment-related adverse events were mild to resistance with anthracyclines. Numerous studies presented moderate. Conclusion: Mitomycin C and capecitabine is a high response rates, especially in patients with prior good taxane-free option in patients with metastatic breast anthracycline-based therapies. As a monotherapy, mitomycin cancer previously treated with anthracycline. achieves response rates of 26-38% in chemotherapy-naïve patients, and in pretreated patients 15-25% (7). The duration Worldwide, breast cancer is the most common malignancy of remission is usually 3-4 months. among women, with an estimated incidence of 1,38 million, The advantages of capecitabine are its oral bioavailability, and is the leading cause of cancer-related deaths in women which is especially appreciated by patients in the palliative (1). Although significant progress has been achieved for the setting (8), its possibility to cross the blood–brain barrier for therapy of early breast cancer, metastatic breast cancer an effective option in the treatment of patients with metastases of the central nervous system (9), and its additive effect with other cytotoxic agents, such as mitomycin C, cyclophosphamide, paclitaxel and docetaxel (10), which can Correspondence to: Michael P. Lux, MD, University Breast-Center be attributed to the up-regulation of the key enzyme thymidine of Franconia, Department of Gynecology and Obstetrics, University phosphorylase in capecitabine metabolism. Several studies Hospital of Erlangen, CCC Erlangen-EMN, Universitaetsstr. 21-23, have demonstrated a well-tolerable side-effect profile of 91054 Erlangen, Germany. Tel: +49 91318533553, e-mail: capecitabine, while taxane-specific side-effects such as high- [email protected] grade neuropathy or neutropenia have not been reported (11). Key Words: Breast cancer, mitomycin C, capecitabine, metastasis, The aim of this single-arm, prospective, multicenter phase chemotherapy. II trial (MiX) was to analyze further taxane-free treatment 0250-7005/2016 $2.00+.40 419 ANTICANCER RESEARCH 36: 419-426 (2016) options for patients with metastatic breast cancer who had of study randomization and the date of progressive disease. Patients undergone at least one prior treatment including an who had no progressive disease were censored at the date of their anthracycline. last clinical visit. Overall survival (OS) was defined as the time interval from the date of study randomization to either the date of Patients and Methods death or the date of the last contact the patient was alive. Patients who were lost to follow-up within 28 days after the last therapy of a maximum of six cycles were censored at the last date they were Primary and secondary end-points. The primary end-point was to known to be alive. A patient who was alive 28 days after diagnosis determine the tumor response according to the Response Evaluation was censored at that date. The data are described using simple Criteria in Solid Tumors (RECIST) (12) and the rate of toxicities survival analyses. Survival rates were estimated using the (safety). The secondary study objective was the evaluation of the Kaplan–Meier product-limit method. time to progression (i.e. efficacy). The clinical cut-off point of the study was 28 days after the last therapy of a maximum of six cycles. Inclusion and exclusion criteria. Eligible patients were women with metastatic breast cancer with at least one measurable lesion according to RECIST. Patients were between 18 and 80 years of Results age, with a Karnofsky performance status of 70% or more. All patients had received a prior anthracycline-containing therapy in the curative or metastatic setting. Patients were required to have normal Demographic data and medical history. Data of 34 patients baseline laboratory results within certain limits. All included women were analyzed. Five patients were excluded due to protocol gave their informed consent for participation in this study. The study violations (no prior anthracycline-containing therapy). All was approved by the Ethics Committee of the Friedrich Alexander patients received at least one cycle of mitomycin C in University Erlangen-Nuremberg, Germany (no. 3026). combination with capecitabine. Assessed with the Karnofsky The main specific exclusion criteria were previous treatment with performance status, 21 patients (61.8%) had normal activity mitomycin C at any time, or with nitrosoureas or capecitabine within and 12 (35.3%) had reduced activity. The mean body mass six weeks prior to the study treatment, major surgery or radiotherapy 2 2 within four weeks before the start of therapy, inadequate recovery index was 27.5 kg/m (range=19.1-43.6 kg/m ). Patients’ from previous therapy, previous or concurrent malignancy (except demographic data are summarized in Table I. The median basal cell carcinoma of the skin, in situ cervical cancer or age at the time of the primary diagnosis of breast cancer was contralateral breast cancer), unstable health, mental illness, addiction, 47 years (range=30-68 years) and median age at the start of cardiovascular disease, myocardial infarction within the last 12 study treatment was 52 years (range=38-71 years). months, or a life expectancy of less than 3 months. The average interval between the first diagnosis of Study design and treatment. This was a single-arm prospective metastases (median age at diagnosis of metastases=51 years) multicenter phase II study. Patients were enrolled at four German and the start of treatment was 14.88 months (range=0-73 centers in Bavaria: the University Breast Center of Franconia at the months). Twenty-eight (82.4%) of the primary tumors were University Hospital of Erlangen; the Department of Gynecology and estrogen receptor-positive and twenty (60.6%) were Obstetrics at the Ludwig Maximilian University of Munich; the progesterone receptor-positive. Ten (41.7%) cases were Department of Gynecology and Obstetrics at the St. Marien Hospital found to have overexpression of human epidermal growth of Amberg; and an oncological practice in the city of Weiden. factor receptor 2, of which four patients (40.0%, two in the Patients received mitomycin C as an intravenous bolus of 8 mg/m2 on day 1, in combination with 2,000 mg/m2 capecitabine on days 1 curative and two in the metastatic setting) received a targeted to 14, of a 21-day cycle. The treatment was continued for a therapy with trastuzumab. Thirty patients (91.0%) had maximum of six cycles or until tumor progression within 18 weeks. undergone previous surgery, all of them in the curative setting. Three patients had no surgery at any time point. Study assessments. Tumor response was evaluated by RECIST after Twenty-two patients (64.7%) had received radiotherapy. the fourth and sixth cycle. The best overall response was evaluated. Twenty-four patients (70.6%) had multiple sites of Time to progression was defined as the interval between metastasis. The most common metastatic sites were the liver randomization and tumor progression, death or loss to follow up in (61.8%), bone (50%), lymph nodes (29.4%), skin (26.5%) patients with no evidence of disease progression. Safety was evaluated in all patients. Toxicities were graded 1 to and lung (26.5%). 5 in accordance with the National Cancer Institute of Common The patients’ medical histories are summarized in Table Toxicity Criteria, version 2.0 (13). If the study treatment had to be II. Thirty-one patients (91.2%) had received chemotherapy discontinued due to toxicities, patients were included in the follow- in the curative setting (29.4% neoadjuvant and 61.8% up. The duration of the follow-up was 18 months after the last adjuvant), 24 patients (70.6%) had received adjuvant therapy of a maximum of six cycles.
Load more

Recommended publications
  • Chemotherapeutic Agents for Brain Metastases in Non-Small Cell Lung
    Fuentes et al. Clin Med Rev Case Rep 2016, 3:107 Volume 3 | Issue 5 Clinical Medical Reviews ISSN: 2378-3656 and Case Reports Case Report: Open Access Chemotherapeutic Agents for Brain Metastases in Non-Small Cell Lung Cancer: A Case Report with Eribulin Mesylate and Review of the Literature Alejandra C Fuentes1, Reordan O De Jesus2 and David N Reisman3* 1Department of Internal Medicine, University of Florida, Gainesville, FL, USA 2Department of Radiology, University of Florida, Gainesville, FL, USA 3Department of Medicine, Division of Hematology/Oncology, University of Florida, Gainesville, FL, USA *Corresponding author: David N Reisman M.D., Ph.D, Department of Medicine, Division of Hematology/ Oncology, University of Florida, PO Box 100278, Gainesville, FL 32610-0278, USA, Tel: 352-273-7832, E-mail: [email protected] nervous system (CNS), where systemic chemotherapy has had poor Abstract penetration. Lung cancer accounts for the majority of cases of brain metastases, resulting in higher morbidity and mortality. Surgery and radiation are The standard treatment options for BM include surgical resection the current standard of care for the treatment of brain metastases. or stereotactic radio surgery (SRS) for patients with a limited number However, when brain metastases recur despite these treatments, of lesions (3-4), and whole brain radiation therapy (WBRT) for the management options are limited, especially when recurrent multiple lesions. What has not been well defined in the treatment of metastatic events occur. The role of systemic chemotherapy BM is the role of systemic chemotherapy [5]. Systemic chemotherapy for brain metastases remains undefined, with advances in drug has been found in some evidence-based studies to show no survival delivery and ongoing studies using targeted agents showing benefit in the treatment of BM [5,6].
    [Show full text]
  • HALAVEN™ Safely and Effectively
    HIGHLIGHTS OF PRESCRIBING INFORMATION ----------------WARNINGS AND PRECAUTIONS---------- These highlights do not include all the information needed to use • Neutropenia: Monitor peripheral blood cell counts and adjust HALAVEN™ safely and effectively. See full prescribing dose as appropriate (2.2, 5.1, 6). information for HALAVEN. • Peripheral Neuropathy: Monitor for signs of neuropathy. HALAVEN™ (eribulin mesylate) Injection Manage with dose delay and adjustment (2.2, 5.2, 6). For intravenous administration only. • Use in Pregnancy: Fetal harm can occur when administered to Eisai Inc. a pregnant woman (5.3) (8.1). Initial US Approval: 2010 • QT Prolongation: Monitor for prolonged QT intervals in patients with congestive heart failure, bradyarrhythmias, drugs ------------------INDICATIONS AND USAGE----------------- known to prolong the QT interval, and electrolyte • HALAVEN is a microtubule inhibitor indicated for the abnormalities. Avoid in patients with congenital long QT treatment of patients with metastatic breast cancer who have syndrome (5.4). previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Prior therapy should have included an anthracycline and a taxane in either the ----------------------ADVERSE REACTIONS------------------ adjuvant or metastatic setting (1). The most common adverse reactions (incidence ≥25%) were neutropenia, anemia, asthenia/fatigue, alopecia, peripheral neuropathy, nausea, and constipation (6). --------------DOSAGE AND ADMINISTRATION------------ • Administer 1.4 mg/m2 intravenously over 2 to 5 minutes on To report SUSPECTED ADVERSE REACTIONS, contact Days 1 and 8 of a 21-day cycle (2.1). Eisai Inc. at (1-877-873-4724) or contact FDA at 1-800-FDA- • Reduce dose in patients with hepatic impairment and moderate 1088 or www.fda.gov/medwatch renal impairment (2.1).
    [Show full text]
  • Induction with Mitomycin C, Doxorubicin, Cisplatin And
    British Journal of Cancer (1999) 80(12), 1962–1967 © 1999 Cancer Research Campaign Article no. bjoc.1999.0627 Induction with mitomycin C, doxorubicin, cisplatin and maintenance with weekly 5-fluorouracil, leucovorin for treatment of metastatic nasopharyngeal carcinoma: a phase II study RL Hong1, TS Sheen2, JY Ko2, MM Hsu2, CC Wang1 and LL Ting3 Departments of 1Oncology, 2Otolaryngology and 3Radiation Therapy, National Taiwan University Hospital, National Taiwan University, No. 7, Chung-Shan South Road, Taipei 10016, Taiwan Summary The combination of cisplatin and 5-fluorouracil (5-FU) (PF) is the most popular regimen for treating metastatic nasopharyngeal carcinoma (NPC) but it is limited by severe stomatitis and chronic cisplatin-related toxicity. A novel approach including induction with mitomycin C, doxorubicin and cisplatin (MAP) and subsequent maintenance with weekly 5-FU and leucovorin (FL) were designed with an aim to reduce acute and chronic toxicity of PF. Thirty-two patients of NPC with measurable metastatic lesions in the liver or lung were entered into this phase II trial. Mitomycin C 8 mg m–2, doxorubicin 40 mg m–2 and cisplatin 60 mg m–2 were given on day 1 every 3 weeks as initial induction. After either four courses or remission was achieved, patients received weekly dose of 5-FU 450 mg m–2 and leucovorin 30 mg m–2 for maintenance until disease progression. With 105 courses of MAP given, 5% were accompanied by grade 3 and 0% were accompanied by grade 4 stomatitis. The dose-limiting toxicity of MAP was myelosuppression. Forty per cent of courses had grade 3 and 13% of courses had grade 4 leukopenia.
    [Show full text]
  • The Limitations of DNA Interstrand Cross-Link Repair in Escherichia Coli
    Portland State University PDXScholar Dissertations and Theses Dissertations and Theses 7-12-2018 The Limitations of DNA Interstrand Cross-link Repair in Escherichia coli Jessica Michelle Cole Portland State University Follow this and additional works at: https://pdxscholar.library.pdx.edu/open_access_etds Part of the Biology Commons Let us know how access to this document benefits ou.y Recommended Citation Cole, Jessica Michelle, "The Limitations of DNA Interstrand Cross-link Repair in Escherichia coli" (2018). Dissertations and Theses. Paper 4489. https://doi.org/10.15760/etd.6373 This Thesis is brought to you for free and open access. It has been accepted for inclusion in Dissertations and Theses by an authorized administrator of PDXScholar. Please contact us if we can make this document more accessible: [email protected]. The Limitations of DNA Interstrand Cross-link Repair in Escherichia coli by Jessica Michelle Cole A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science in Biology Thesis Committee: Justin Courcelle, Chair Jeffrey Singer Rahul Raghavan Portland State University 2018 i Abstract DNA interstrand cross-links are a form of genomic damage that cause a block to replication and transcription of DNA in cells and cause lethality if unrepaired. Chemical agents that induce cross-links are particularly effective at inactivating rapidly dividing cells and, because of this, have been used to treat hyperproliferative skin disorders such as psoriasis as well as a variety of cancers. However, evidence for the removal of cross- links from DNA as well as resistance to cross-link-based chemotherapy suggests the existence of a cellular repair mechanism.
    [Show full text]
  • BC Cancer Benefit Drug List September 2021
    Page 1 of 65 BC Cancer Benefit Drug List September 2021 DEFINITIONS Class I Reimbursed for active cancer or approved treatment or approved indication only. Reimbursed for approved indications only. Completion of the BC Cancer Compassionate Access Program Application (formerly Undesignated Indication Form) is necessary to Restricted Funding (R) provide the appropriate clinical information for each patient. NOTES 1. BC Cancer will reimburse, to the Communities Oncology Network hospital pharmacy, the actual acquisition cost of a Benefit Drug, up to the maximum price as determined by BC Cancer, based on the current brand and contract price. Please contact the OSCAR Hotline at 1-888-355-0355 if more information is required. 2. Not Otherwise Specified (NOS) code only applicable to Class I drugs where indicated. 3. Intrahepatic use of chemotherapy drugs is not reimbursable unless specified. 4. For queries regarding other indications not specified, please contact the BC Cancer Compassionate Access Program Office at 604.877.6000 x 6277 or [email protected] DOSAGE TUMOUR PROTOCOL DRUG APPROVED INDICATIONS CLASS NOTES FORM SITE CODES Therapy for Metastatic Castration-Sensitive Prostate Cancer using abiraterone tablet Genitourinary UGUMCSPABI* R Abiraterone and Prednisone Palliative Therapy for Metastatic Castration Resistant Prostate Cancer abiraterone tablet Genitourinary UGUPABI R Using Abiraterone and prednisone acitretin capsule Lymphoma reversal of early dysplastic and neoplastic stem changes LYNOS I first-line treatment of epidermal
    [Show full text]
  • Sex-Specific Effects of Cytotoxic Chemotherapy Agents
    www.impactaging.com AGING, April 2016, Vol 8 No 4 Research Paper Sex‐specific effects of cytotoxic chemotherapy agents cyclophospha‐ mide and mitomycin C on gene expression, oxidative DNA damage, and epigenetic alterations in the prefrontal cortex and hippocampus – an aging connection 1 2 2 2 Anna Kovalchuk , Rocio Rodriguez‐Juarez , Yaroslav Ilnytskyy , Boseon Byeon , Svitlana 3,4 4 3 1,5,6 2,5 Shpyleva , Stepan Melnyk , Igor Pogribny , Bryan Kolb, , and Olga Kovalchuk 1 Department of Neuroscience, University of Lethbridge, Lethbridge, AB, T1K3M4, Canada 2 Department of Biological Sciences, University of Lethbridge, Lethbridge, AB, T1K3M4, Canada 3 Division of Biochemical Toxicology, Food and Drug Administration National Center for Toxicological Research, Jefferson, AR 72079, USA 4Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, AR 72202, USA 5 Alberta Epigenetics Network, Calgary, AB, T2L 2A6, Canada 6 Canadian Institute for Advanced Research, Toronto, ON, M5G 1Z8, Canada Key words: chemotherapy, chemo brain, epigenetics, DNA methylation, DNA hydroxymethylation, oxidative stress, transcriptome, aging Received: 01/08/16; Accepted: 01/30/1 6; Published: 03/30/16 Corresponden ce to: Bryan Kolb, PhD; Olga Kovalchuk, PhD; E‐mail: [email protected]; [email protected] Copyright: Kovalchuk et al. This is an open‐access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited Abstract: Recent research shows that chemotherapy agents can be more toxic to healthy brain cells than to the target cancer cells. They cause a range of side effects, including memory loss and cognitive dysfunction that can persist long after the completion of treatment.
    [Show full text]
  • Intravesical Administration of Therapeutic Medication for the Treatment of Bladder Cancer Jointly Developed with the Society of Urologic Nurses and Associates (SUNA)
    Intravesical Administration of Therapeutic Medication for the Treatment of Bladder Cancer Jointly developed with the Society of Urologic Nurses and Associates (SUNA) Revised: June 2020 Workgroup Members: AUA: Roxy Baumgartner, RN, APN-BC; Sam Chang, MD; Susan Flick, CNP; Howard Goldman, MD, FACS; Jim Kovarik, MS, PA-C; Yair Lotan, MD; Elspeth McDougall, MD, FRCSC, MHPE; Arthur Sagalowsky, MD; Edouard Trabulsi, MD SUNA: Debbie Hensley, RN; Christy Krieg, MSN, CUNP; Leanne Schimke, MSN, CUNP I. Statement of Purpose: To define the performance guidance surrounding the instillation of intravesical cytotoxic, immunotherapeutic, and/or therapeutic drugs via sterile technique catheterization for patients with non-muscle invasive bladder cancer (NMIBC, urothelial carcinoma). II. Population: Adult Urology III. Definition: Intravesical therapy involves instillation of a therapeutic agent directly into the bladder via insertion of a urethral catheter. IV. Indications: For administration of medication directly into the bladder via catheterization utilizing sterile technique for NMIBC treatment. V. Guidelines and Principles: Health care personnel (MD, NP, PA, RN, LPN, or MA) performing intravesical therapy must be educated, demonstrate competency, and understand the implications of non-muscle invasive bladder cancer. (Scope of practice for health care personnel listed may vary based on state or institution). This should include associated health and safety issues regarding handling of cytotoxic, and immunotherapeutic agents; and documented competency of safe practical skills. At a minimum, each institution or office practice setting should implement an established, annual competency program to review safety work practices and guidelines regarding storage, receiving, handling/ transportation, administration, disposal, and handling a spill of hazardous drugs. (Mellinger, 2010) VI.
    [Show full text]
  • Insensitive Tumor Cells
    Global Journal of Cancer Therapy eertechz Richard J Rickles1, Junji Matsui3, Ping Research Article Zhu1, Yasuhiro Funahashi2,3, Jill M Grenier1, Janine Steiger1, Nanding Zhao2, Bruce A Littlefield2, Kenichi Identification of Combinatorial Nomoto2,3 and Toshimitsu Uenaka2* 1Horizon Discovery Inc., MA, Japan Drugs that Synergistically Kill both 2Eisai Inc., MA, Japan 3Eisai Co., Ltd., Japan Eribulin-Sensitive and Eribulin- Dates: Received: 17 October, 2015; Accepted: 03 November, 2015; Published: 04 November, 2015 Insensitive Tumor Cells *Corresponding author: Toshimitsu Uenaka, Ph.D., Executive Director, Production Creation Headquarter, Oncology & Antibody Drug Strategy, CINO (Chief Abstract Innovation Officer), E-mail: Eribulin sensitivity was examined in a panel of twenty-five human cancer cell lines representing a www.peertechz.com variety of tumor types, with a preponderance of breast and lung cancer cell lines. As expected, the cell lines vary in sensitivity to eribulin at clinically relevant concentrations. To identify combination drugs capable of increasing anticancer effects in patients already responsive to eribulin, as well as inducing de novo anticancer effects in non-responders, we performed a combinatorial high throughput screen to identify drugs that combine with eribulin to selectively kill tumor cells. Among other observations, we found that inhibitors of ErbB1/ErbB2 (lapatinib, BIBW-2992, erlotinib), MEK (E6201, trametinib), PI3K (BKM-120), mTOR (AZD 8055, everolimus), PI3K/mTOR (BEZ 235), and a BCL2 family antagonist (ABT-263) show combinatorial activity with eribulin. In addition, antagonistic pairings with other agents, such as a topoisomerase I inhibitor (topotecan hydrochloride), an HSP-90 inhibitor (17-DMAG), and gemcitabine and cytarabine, were identified. In summary, the preclinical studies described here have identified several combination drugs that have the potential to either augment or antagonize eribulin’s anticancer activity.
    [Show full text]
  • Halaven® (Eribulin)
    Halaven® (eribulin) (Intravenous) Document Number: IC-0055 Last Review Date: 03/01/2021 Date of Origin: 03/2012 Dates Reviewed: 06/2012, 09/2012, 12/2012, 03/2013, 06/2013, 09/2013, 12/2013, 03/2014, 06/2014, 09/2014, 12/2014, 03/2015, 05/2015, 08/2015, 11/2015, 02/2016, 05/2016, 08/2016, 11/2016, 02/2017, 05/2017, 08/2017, 11/2017, 02/2018, 05/2018, 09/2018, 12/2018, 03/2019, 06/2019, 09/2019, 12/2019, 03/2020, 06/2020, 09/2020, 03/2021 I. Length of Authorization Coverage will be provided for six months and may be renewed. II. Dosing Limits A. Quantity Limit (max daily dose) [NDC Unit]: • Halaven 1 mg/2 mL solution for injection: 8 vials every 21 days B. Max Units (per dose and over time) [HCPCS Unit]: • 80 billable units every 21 days III. Initial Approval Criteria 1 Coverage is provided in the following conditions: • Patient is at least 18 years of age; AND Breast Cancer † 1-3 • Patient has metastatic disease †; AND o Used as a single agent for patients who have previously received at least two chemotherapy regimens for the treatment of metastatic disease; AND o Prior therapy includes treatment with an anthracycline and a taxane in either the adjuvant or metastatic setting; OR • Patient has recurrent or metastatic disease; AND o Used as a single agent for human epidermal growth factor receptor 2 (HER2)-negative disease and one of the following: − Disease is hormone receptor negative; OR Proprietary & Confidential © 2021 Magellan Health, Inc. − Disease is hormone receptor positive with visceral crisis or refractory to endocrine therapy; OR o Used in combination with trastuzumab for HER2-positive disease Liposarcoma † 1,4 • Used as a single agent; AND • Patient has unresectable or metastatic or recurrent disease; AND • Patient has received prior anthracycline-based therapy (e.g.
    [Show full text]
  • ERG Induces Taxane Resistance in Castration-Resistant Prostate Cancer
    ARTICLE Received 27 Jul 2014 | Accepted 9 Oct 2014 | Published 25 Nov 2014 DOI: 10.1038/ncomms6548 OPEN ERG induces taxane resistance in castration-resistant prostate cancer Giuseppe Galletti1, Alexandre Matov1,2, Himisha Beltran1,3, Jacqueline Fontugne4, Juan Miguel Mosquera3,4, Cynthia Cheung4, Theresa Y. MacDonald4, Matthew Sung1, Sandra O’Toole5,6, James G. Kench5,6, Sung Suk Chae4, Dragi Kimovski2, Scott T. Tagawa1,7, David M. Nanus1,7, Mark A. Rubin3,4,7, Lisa G. Horvath5,6,8, Paraskevi Giannakakou1,7,* & David S. Rickman3,4,7,* Taxanes are the only chemotherapies used to treat patients with metastatic castration- resistant prostate cancer (CRPC). Despite the initial efficacy of taxanes in treating CRPC, all patients ultimately fail due to the development of drug resistance. In this study, we show that ERG overexpression in in vitro and in vivo models of CRPC is associated with decreased sensitivity to taxanes. ERG affects several parameters of microtubule dynamics and inhibits effective drug-target engagement of docetaxel or cabazitaxel with tubulin. Finally, analysis of a cohort of 34 men with metastatic CRPC treated with docetaxel chemotherapy reveals that ERG-overexpressing prostate cancers have twice the chance of docetaxel resistance than ERG-negative cancers. Our data suggest that ERG plays a role beyond regulating gene expression and functions outside the nucleus to cooperate with tubulin towards taxane insensitivity. Determining ERG rearrangement status may aid in patient selection for docetaxel or cabazitaxel therapy and/or influence co-targeting approaches. 1 Department of Medicine, Weill Cornell Medical College, New York, New York 10065, USA. 2 University for Information Science and Technology St Paul the Apostle, Ohrid 6000, Macedonia.
    [Show full text]
  • Chemotherapy and Polyneuropathies Grisold W, Oberndorfer S Windebank AJ European Association of Neurooncology Magazine 2012; 2 (1) 25-36
    Volume 2 (2012) // Issue 1 // e-ISSN 2224-3453 Neurology · Neurosurgery · Medical Oncology · Radiotherapy · Paediatric Neuro- oncology · Neuropathology · Neuroradiology · Neuroimaging · Nursing · Patient Issues Chemotherapy and Polyneuropathies Grisold W, Oberndorfer S Windebank AJ European Association of NeuroOncology Magazine 2012; 2 (1) 25-36 Homepage: www.kup.at/ journals/eano/index.html OnlineOnline DatabaseDatabase FeaturingFeaturing Author,Author, KeyKey WordWord andand Full-TextFull-Text SearchSearch THE EUROPEAN ASSOCIATION OF NEUROONCOLOGY Member of the Chemotherapy and Polyneuropathies Chemotherapy and Polyneuropathies Wolfgang Grisold1, Stefan Oberndorfer2, Anthony J Windebank3 Abstract: Peripheral neuropathies induced by taxanes) immediate effects can appear, caused to be caused by chemotherapy or other mecha- chemotherapy (CIPN) are an increasingly frequent by different mechanisms. The substances that nisms, whether treatment needs to be modified problem. Contrary to haematologic side effects, most frequently cause CIPN are vinca alkaloids, or stopped due to CIPN, and what symptomatic which can be treated with haematopoetic taxanes, platin derivates, bortezomib, and tha- treatment should be recommended. growth factors, neither prophylaxis nor specific lidomide. Little is known about synergistic neu- Possible new approaches for the management treatment is available, and only symptomatic rotoxicity caused by previously given chemo- of CIPN could be genetic susceptibility, as there treatment can be offered. therapies, or concomitant chemotherapies. The are some promising advances with vinca alka- CIPN are predominantly sensory, duration-of- role of pre-existent neuropathies on the develop- loids and taxanes. Eur Assoc Neurooncol Mag treatment-dependent neuropathies, which de- ment of a CIPN is generally assumed, but not 2012; 2 (1): 25–36. velop after a typical cumulative dose. Rarely mo- clear.
    [Show full text]
  • Recent Advances in the Management of Hormone Refractory Prostate Cancer
    Korean J Uro-Oncol 2004;2(3):147-153 Recent Advances in the Management of Hormone Refractory Prostate Cancer Mari Nakabayashi, William K. Oh Lank Center for Genitourinary Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA A typical treatment strategy after AAWD is to use secondary INTRODUCTION hormonal manipulations, although studies have not yet demonstrated a survival benefit with this class of treatment. Prostate cancer is the most common cancer in men in the Options in this category include (1) the secondary use of anti- United States and accounted for 29,900 deaths in 2003.1 androgens (e.g., high-dose bicalutamide, nilutamide), (2) thera- Although most men with advanced prostate cancer respond pies targeted against adrenal steroid synthesis (e.g., ketocona- initially to androgen deprivation therapies (ADT) by either zole, corticosteroids), and (3) estrogenic therapies (e.g. diethy- bilateral orchiectomy or leuteinizing hormone releasing hor- lstilbestrol). Symptomatic improvement and PSA responses mone (LHRH) analogues, patients eventually progress to an (defined as PSA decline ＞50% after treatment) have been androgen-independent state in which the initial ADT no longer reported in approximately 20% to 80% of patients with is adequate to control disease.2 Progression of the disease hormone-refractory prostate cancer (HRPC) with a typical manifests as an increase in serum prostate-specific antigen duration of response of 2 to 6 months. Toxicity is generally (PSA) or may be accompanied by radiographic evidence of mild for these oral therapies, although serious side effects, tumor growth. Here we report a brief summary of recent including adrenal insufficiency, liver toxicity, and thrombosis, advances in the management of hormone refractory prostate may occur (Table 1).
    [Show full text]